Bulletin
Investor Alert

New York Markets Close in:

Harrow Health Inc.

NAS: HROW

GO
/marketstate/country/us

Market open

 --Real time quotes

Jul 6, 2022, 12:37 p.m.

/zigman2/quotes/206805265/composite

$

7.10

Change

+0.07 +1.00%

Volume

Volume 11,520

Real time quotes

/zigman2/quotes/206805265/composite

Previous close

$ 7.03

$ 7.10

Change

+0.07 +1.00%

Day low

Day high

$6.91

$7.10

Open

52 week low

52 week high

$5.40

$12.99

Open

Company Description

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The comp...

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Valuation

Price to Sales Ratio

3.19

Price to Book Ratio

20.60

Price to Cash Flow Ratio

45.49

Enterprise Value to EBITDA

52.26

Enterprise Value to Sales

2.75

Efficiency

Total Asset Turnover

0.93

Liquidity

Current Ratio

6.24

Quick Ratio

5.81

Cash Ratio

5.21

Profitability

Gross Margin

74.87

Operating Margin

2.43

Pretax Margin

-24.80

Net Margin

-24.85

Return on Assets

-23.12

Return on Equity

-93.62

Return on Total Capital

2.53

Capital Structure

Total Debt to Total Assets

79.28

Officers and Executives

Name Age Officer Since Title
Mr. Mark L. Baum 47 2006 Chief Executive Office & Director
Mr. Andrew R. Boll 37 2011 Chief Financial Officer & Secretary
Dr. Larry M. Dillaha 55 - Chief Medical Officer
Mr. Andrew Livingston - - Chief Innovation Officer
Mr. John P. Saharek 60 2012 Vice President-Commercialization

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
04/13/2022 Opaleye Management, Inc.
2,832   Acquisition at $6.76 per share. 19,144
04/13/2022 Opaleye Management, Inc.
10,000   Acquisition at $6.76 per share. 67,600
04/12/2022 Opaleye Management, Inc.
3,557   Acquisition at $6.75 per share. 24,009
04/12/2022 Opaleye Management, Inc.
25,000   Acquisition at $6.75 per share. 168,750
02/19/2022 Andrew R. Boll
Chief Financial Officer
20,605   Derivative/Non-derivative trans. at $7.87 per share. 162,161
02/19/2022 John P. Saharek
President, ImprimisRx
25,923   Derivative/Non-derivative trans. at $7.87 per share. 204,014
02/19/2022 Andrew R. Boll
Chief Financial Officer
50,000   Derivative/Non-derivative trans. at $0 per share. 0
02/19/2022 John P. Saharek
President, ImprimisRx
50,000   Derivative/Non-derivative trans. at $0 per share. 0
01/28/2022 Opaleye Management, Inc.
1,343   Acquisition at $6.89 per share. 9,253
01/28/2022 Opaleye Management, Inc.
5,000   Acquisition at $6.89 per share. 34,450
01/20/2022 Mark L. Baum
Chief Executive Officer; Director
71,406   Derivative/Non-derivative trans. at $8.33 per share. 594,811
01/20/2022 Mark L. Baum
Chief Executive Officer; Director
125,000   Derivative/Non-derivative trans. at $2.4 per share. 300,000
09/24/2021 Richard L. Lindstrom
Director
3,900   Disposition at $10.04 per share. 39,156
09/16/2021 Richard L. Lindstrom
Director
5,840   Disposition at $9.02 per share. 52,676
09/15/2021 Richard L. Lindstrom
Director
14,160   Disposition at $9.09 per share. 128,714
08/19/2021 Opaleye Management, Inc.
2,500   Acquisition at $8.44 per share. 21,100
08/19/2021 Opaleye Management, Inc.
50,000   Acquisition at $8.44 per share. 422,000
08/18/2021 Opaleye Management, Inc.
1,500   Acquisition at $8.64 per share. 12,960
08/18/2021 Opaleye Management, Inc.
45,000   Acquisition at $8.64 per share. 388,800
/news/latest/company/us/hrow

MarketWatch News on HROW

  1. Imprimis Pharma initiated as buy at B Riley FBR

    3:11 p.m. Dec. 13, 2018

    - Ciara Linnane

  2. Express Scripts opts for $1 alternative to Turing’s $750 Daraprim

    6:56 a.m. Dec. 1, 2015

    - Jonathan D. Rockoff

  3. Duckburg Economics: Pricing and Scarcity in Drugs

    12:44 a.m. Oct. 31, 2015

    - Barron's Online

/news/nonmarketwatch/company/us/hrow

Other News on HROW

  1. Harrow Health files for $300M mixed shelf offering

    5:44 p.m. May 26, 2022

    - Seeking Alpha

  2. 10-Q: HARROW HEALTH, INC.

    4:48 p.m. May 5, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  3. Harrow Health, Inc. 2021 Q4 - Results - Earnings Call Presentation

    10:35 a.m. March 11, 2022

    - Seeking Alpha

  4. 10-K: HARROW HEALTH, INC.

    5:48 p.m. March 10, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  5. SRK Capital Q4 2021 Investor Letter

    2:21 p.m. Feb. 11, 2022

    - Seeking Alpha

  6. Select Medical's (SEM) Rising Stake in Concentra to Aid

    11:24 a.m. Dec. 30, 2021

    - Zacks.com

  7. Acadia (ACHC) & Orlando Health Form JV, Boosts Presence

    11:05 a.m. Dec. 2, 2021

    - Zacks.com

  8. Why Seasoned Investors are Retaining Acadia (ACHC) Stock

    11:50 a.m. Nov. 30, 2021

    - Zacks.com

  9. Harrow Health: Our 3rd Quarter Update On This Promising Company

    12:49 p.m. Nov. 26, 2021

    - Seeking Alpha

  10. Teladoc (TDOC) Falls 8.1% Despite Upbeat Revenue Guidance

    1:06 p.m. Nov. 19, 2021

    - Zacks.com

  11. Loading more headlines...

At a Glance

Harrow Health, Inc.

102 Woodmont Boulevard

Suite 610

Nashville, Tennessee 37205

Phone

1 6157334730

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$72.48M

Net Income

$-18.01M

Employees

182.00

/news/pressrelease/company/us/hrow

Press Releases on HROW

  1. Harrow Health Announces First Quarter 2022 Financial Results

    4:01 p.m. May 5, 2022

    - BusinessWire - BZX

  2. Harrow Health Announces Appointments to Its Board of Directors

    7:00 a.m. March 31, 2022

    - BusinessWire - BZX

  3. Harrow Health to Present at Aegis Virtual Conference

    8:00 a.m. Feb. 15, 2022

    - BusinessWire - BZX

  4. Harrow Health Publishes Corporate Transparency Report

    9:00 a.m. Feb. 8, 2022

    - BusinessWire - BZX

  5. Harrow Health to Participate in H.C. Wainwright BioConnect Conference

    7:45 a.m. Jan. 10, 2022

    - BusinessWire - BZX

  6. Melt Pharmaceuticals Submits INDs for MELT‘210 and MELT-400 to FDA

    9:00 a.m. Jan. 4, 2022

    - BusinessWire - BZX

  7. Harrow Health Added to the Nasdaq Biotechnology Index

    9:00 a.m. Dec. 13, 2021

    - BusinessWire - BZX

  8. Harrow Health Announces Third Quarter 2021 Financial Results

    5:01 p.m. Nov. 9, 2021

    - BusinessWire - BZX

  9. Loading more headlines...
Link to MarketWatch's Slice.